ArticleMolecular oncology2021

An in vivo genome-wide shRNA screen identifies BCL6 as a targetable biomarker of paclitaxel resistance in breast cancer.

Mohammad Sultan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.